Coya Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Coya Therapeutics, Inc. | ||
| Date: March 19, 2024 | By: | /s/ Howard Berman |
|---|---|---|
| Name: Howard Berman | ||
| Title: Chief Executive Officer | ||
| Date: March 19, 2024 | By: | /s/ David Snyder |
| Name: David Snyder | ||
| Title: Chief Financial Officer (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Howard Berman | Chief Executive Officer and Director | March 19, 2024 |
| Howard Berman | (Principal Executive Officer) | |
| /s/ David Snyder | Chief Financial Officer | March 19, 2024 |
| David Snyder | (Principal Financial and Accounting Officer) | |
| Chief Operating Officer | ||
| /s/ Ann Lee | Director | March 19, 2024 |
| Ann Lee | ||
| /s/ Anabella Villalobos | Director | March 19, 2024 |
| Anabella Villalobos | ||
| /s/ Hideki Garren | Director | March 19, 2024 |
| Hideki Garren | ||
| /s/ Dov Goldstein | Director | March 19, 2024 |
| Dov Goldstein | ||
| /s/ Dieter Weinand | Director | March 19, 2024 |
|---|---|---|
| Dieter Weinand | ||
| /s/ Wilbur L. Ross | Director | March 19, 2024 |
| Wilbur Ross | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | 93 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | 94 |
| Statements of Operations for the Years ended December 31, 2023 and 2022 | 95 |
| Statements of Stockholders’ Equity (Deficit) for the Years ended December 31, 2023 and 2022 | 96 |
| Statements of Cash Flows for the Years ended December 31, 2023 and 2022 | 97 |
| Notes to Financial Statements | 98 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.